M&A Deal Summary |
|
---|---|
Date | 2013-03-20 |
Target | Obagi |
Sector | Consumer Products |
Buyer(s) | Bausch Health |
Deal Type | Add-on Acquisition |
Deal Value | 360M USD |
Advisor(s) | Morgan Stanley (Financial) |
SEARCH BY
Try For Free 7-Day Free Trial
Category | Company |
---|---|
Sector | Life Science |
Employees | 20,270 |
Revenue | 8.8B USD (2023) |
Bausch Health is a multinational specialty pharmaceutical company that develops, manufactures and markets a broad range of pharmaceutical products primarily in the areas of dermatology, neurology, and branded generics. Bausch Health is based in Laval, Quebec.
DEAL STATS | # |
---|---|
Overall | 23 of 35 |
Sector (Consumer Products) | 5 of 6 |
Type (Add-on Acquisition) | 16 of 25 |
State (California) | 4 of 6 |
Country (United States) | 11 of 22 |
Year (2013) | 2 of 4 |
Size (of disclosed) | 11 of 27 |
DATE | TARGET | DEAL TYPE | VALUE |
---|---|---|---|
2013-02-01 |
Natur Produkt
Saint Petersburg, Russia Natur Produkt provides (OTC) drugs segment in several categories marketed under the umbrella brand, Natur Produkt. Key brands include AntiGrippin, a leading cough and cold remedy, Anti Angin, Sage and Eucaplyptus MA. |
Buy | $163M |
DATE | TARGET | DEAL TYPE | VALUE |
---|---|---|---|
2013-05-27 |
Bausch & Lomb
Rochester, New York, United States Bausch & Lomb is a manufacturer of ophthalmic products. |
Buy | $8.7B |